Influence of Residual Bone Height on Marginal Bone Loss Around Implants Following Lateral Sinus Floor Augmentation With Deproteinized Bovine Bone Mineral

Influence of Residual Bone Height on Marginal Bone Loss Around Implants Following Lateral Sinus Floor Augmentation With Deproteinized Bovine Bone Mineral: A Retrospective Study Up to 12 Years.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07550491

Enrollment

142

Registered

2026-04-24

Start date

2026-01-01

Completion date

2026-04-17

Last updated

2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Implant Type, Marginal Bone Loss, Residual Bone Height, Smoking

Keywords

Alveolar bone loss, bone substitutes, dental implant, diabetes mellitus, sinus floor augmentation, smoking

Brief summary

Data collection will be done on all patients who underwent a lateral maxillary sinus floor augmentation in the Faculty of Dental Medicine, both in the Periodontology Department and in the Oral Surgery Department. Pre-surgical residual bone height will be measured on patients with a preoperative CBCT, and marginal bone loss will be measured in patients with a postoperative periapical radiograph that dates at least 3 years after implant placement. In contrast to other studies who only associated between the presurgical residual bone height and implant survival / success rate, this study design takes a more in depth approach and measures the exact marginal bone loss on each implant. In addition, other factors will be taken into consideration (implant type, smoking status, diabetes status) to eliminate any confounding factors.

Interventions

PROCEDUREsinus lift using DBBM

Sinus lift was performed to the patients, then after 9 months dental implants were placed.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* All patients who underwent a lateral maxillary sinus floor augmentation using deproteinated bovine bone matrix (DBBM) at the faculty before 2022. * Patients with pre-operative CBCT. * Patients with no visible sinus infection in the pre-operative CBCT.

Exclusion criteria

* Patients who do not have a pre-operative CBCT. * Patients who do not have a post-operative orthogonal periapical radiograph that dates at least 3 years after implant placement. * Presence of inflammatory lesions at the surgical site (eg, sinusitis as assessed by CBCT). * Cases with sinus perforation. * History of radiation therapy in the head/neck region. * Use of bisphosphonates

Design outcomes

Primary

Measure	Time frame	Description
Marginal Bone Loss	at least 3 years after implant placement	mesial and distal marginal bone loss were calculated from the implant platform to the first bone to implant contact

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026